Active Stocks in Review: ARC Document Solutions, Inc. (NYSE:ARC), Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

0

ARC Document Solutions, Inc. (NYSE:ARC)

ARC Document Solutions, Inc. (NYSE:ARC) represented a move of 0 percent or $0.06 per share and closed its previous day trading session at $2.43. 0 Shares were traded in the last trading session with an Average Volume of 204.1 Million Shares. The stock currently has a Market Capitalization of 112.63 Million.

ARC Document Solutions Inc. is a document solutions company providing business-to-business document management technology and services to the architectural, engineering and construction, or AEC industries. It also provides document management services to companies in non-AEC industries, such as technology, financial services, retail, entertainment, and food and hospitality. The Company provides services that include scanning, imaging, and managing black and white and color documents. ARC Document Solutions Inc., formerly known as American Reprographics Company, is headquartered in Walnut Creek, California.

The stock traded between $1.62 and $3.59 over 1-Year time period showing its price to sales ratio of 0.28. ARC Document Solutions, Inc. (NYSE:ARC) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $-5.87 and 200-Day Simple Moving Average of $-0.02. Its Price to Free Cash Flow is 3.37 and Price to Book of 0.79.

Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, ARC Document Solutions, Inc. (NYSE:ARC) reported its Actual EPS of $0.06/share. The analysts offering Earnings Estimates for the company were believing that ARC Document Solutions, Inc. could bring EPS of $0.01/share. The difference between Actual EPS and Estimated EPS was 0.05 Percent. Thus showing an Earnings Surprise of 500 Percent.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

In the last trading session, Nymox Pharmaceutical Corporation (NASDAQ:NYMX) added its value by 0% closing at the price of $1.73. The stock currently has market capitalization of 109.01 Million, with average volume of 136.58 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is showing beta of 0.92. This particular value of beta suggests that Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has historically moved 92% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is at $-0.19.

The stock currently has RSI of 42.01. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

Nymox Pharmaceutical Corporation is engaged in the research and development of drugs and diagnostic products. The company offers products such as AlzheimAlert, NicAlert and TobacAlert tests. It markets its products primarily in the United States, Canada, and Europe. Nymox Pharmaceutical Corporation is based in St Laurent, Canada.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) topped its 52-week high price of $4.60 on 03/28/18 and 52-Week Low Price of $1.49 on 10/23/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 9.64% and monthly volatility of 9.43% respectively.